Akero Therapeutics Inc [AKRO] stock prices are up 0.58% to $48.31 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The AKRO shares have lost -8.49% over the last week, with a monthly amount drifted -6.67%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Akero Therapeutics Inc [NASDAQ: AKRO] stock has seen the most recent analyst activity on August 04, 2025, when TD Cowen initiated its Buy rating and assigned the stock a price target of $76. Previously, BofA Securities upgraded its rating to Buy on January 30, 2025, and elevated its price target to $63. On January 27, 2025, H.C. Wainwright reiterated its Buy rating and revised its price target to $72 on the stock. Citigroup started tracking the stock assigning a Buy rating and suggested a price target of $65 on November 18, 2024. Cantor Fitzgerald started tracking with a Overweight rating for this stock on September 19, 2023, and assigned it a price target of $69. In a note dated August 28, 2023, UBS initiated a Buy rating and provided a target price of $83 on this stock.
The stock price of Akero Therapeutics Inc [AKRO] has been fluctuating between $21.34 and $58.40 over the past year. Currently, Wall Street analysts expect the stock to reach $46 within the next 12 months. Akero Therapeutics Inc [NASDAQ: AKRO] shares were valued at $48.31 at the most recent close of the market. An investor can expect a potential drop of -4.78% based on the average AKRO price forecast.
Analyzing the AKRO fundamentals
Gross Profit Margin for this corporation currently stands at 0.25% with Operating Profit Margin at -80370.75%, Pretax Profit Margin comes in at -70989.75%, and Net Profit Margin reading is -70989.75%. To continue investigating profitability, this company’s Return on Assets is posted at -0.26, Equity is -0.32 and Total Capital is -0.31. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.04.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 47.67 points at the first support level, and at 47.04 for the second support level. However, for the 1st resistance point, the stock is sitting at 48.86, and for the 2nd resistance point, it is at 49.42.
Ratios To Look Out For
It’s worth pointing out that Akero Therapeutics Inc [NASDAQ:AKRO]’s Current Ratio is 12.66. On the other hand, the Quick Ratio is 12.66, and the Cash Ratio is 3.65.
Transactions by insiders
Recent insider trading involved Young Jonathan, Chief Operating Officer, that happened on Aug 12 ’25 when 12500.0 shares were sold. President and CEO, Cheng Andrew completed a deal on Aug 11 ’25 to sell 30000.0 shares. Meanwhile, Director Henderson Jane sold 3000.0 shares on Aug 12 ’25.
